Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
Viridian Therapeutics announced positive topline results from the Phase 3 REVEAL-2 trial of elegrobart in chronic thyroid eye disease (TED), meeting its primary endpoint with high statistical significance. The trial reported proptosis responder rates of 50% and 54% for the Q4W and Q8W dosing regimens, respectively, compared to 15% for placebo, with Q4W also achieving a statistically significant diplopia responder rate of 61%.
Key figures
- Drug Name
- elegrobart
- Phase Of Trial
- Phase 3
- Bla submission timing
- Q1 2027
- Pduea date veligrotug
- June 30, 2026
- Diplopia responder rate q4w
- 61%
- Proptosis responder rate q4w
- 50%
- Proptosis responder rate q8w
- 54%
- Diplopia responder rate placebo
- 38%
- Proptosis responder rate placebo
- 15%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.